CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins85% CONFIDENCEOverall confidence: 85%How well the pin's source and references back up its dates.Weighted average of how firmly 3 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better
Lilly's release announcing the FDA approval is dated 13 May 2022; Healio[1] reports the same.On 13 May 2022 the US FDA approved Mounjaro (tirzepatide, once weekly), the first dual GIP and GLP-1 receptor agonist, opening Eli Lilly's challenge to Novo Nordisk's semaglutide brands.
1.00
